Merck & Company
2000 Galloping Hill Road
About Merck & Company
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
2924 articles with Merck & Company
Acquisition Includes Novel Late-Stage Renal Cell Carcinoma Candidate, PT2977
Sponsorship of NEADS World Class Service Dogs Underscores the Importance of Keeping Pets Protected from Fleas and Ticks
Merck & Co. announced that its Keytruda failed to hit its primary endpoint in the Phase III Keynote-119 clinical trial. The primary endpoint was superior overall survival compared to chemotherapy.
Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.
Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
Merck announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy.
Intec Pharma Ltd. announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to explore using the Accordion Pill® platform for an undisclosed development program.
Hangzhou, capital of east China's Zhejiang Province, has seen seven bio-pharmaceutical projects implemented in the first quarter of the year, with a total investment of 1.5 billion yuan, according to the latest data of the Hangzhou Investment Promotion Bureau on Wednesday.
New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting
Merck, known as MSD outside the United States and Canada, announced that new research from the company’s broad oncology clinical development program will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Merck and Co. announced that its investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age.
Merck is planning a $1 billion expansion to its manufacturing facility in Elkton, Va. over the course of the next three years that will include the addition of approximately 100 new jobs, the office of the governor of Virginia announced Wednesday.
First and Only PARP Inhibitor, Lynparza® (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer - May 8, 2019
AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy
Merck’s BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia
First Randomized Controlled Polysomnography Trial of Insomnia Medication in Alzheimer’s Disease Dementia Population
The company announced today that it had positive results in a Phase III clinical trial evaluating the drug for insomnia in patients with mild-to-moderate Alzheimer’s disease dementia.
For those select few who achieve the role of chief executive officer of a multi-national corporation, the compensation packages are typically quite large – especially when compared to the average salaries of company employees.
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
Merck & Co. filed with the U.S. Securities and Exchange Commission that it plans an extensive restructuring of its manufacturing and supply network. This will, it indicates, reduce its “global real estate footprint.”
First-Quarter 2019 Worldwide Sales Were $10.8 Billion, an Increase of 8%; Sales Increased 11% Excluding Negative Impact from Foreign Exchange; Growth Driven by Oncology and Vaccines
NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.
LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Is the Only PARP Inhibitor in This Setting to Demonstrate an Improvement in Progression-Free Survival for Patients Who Responded to Platinum-Based Chemotherapy